Lean Body Mass and Side Effects in Patients With Lymphoma

Jens Rikardt Andersen

Status: Unknown

Conditions: Malignant Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT04698616

SJ-823

Details and patient eligibility

About

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

Enrollment: 141 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator.
• Legal of age

Exclusion criteria

• ECOG Performance Status ≥2
• People who cannot speak and understand Danish
• Pregnant and breastfeeding
• Dementia

Trial design

141 participants in 1 patient group

Malignant lymphoma patients

Description:

Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.